Coave has raised €32m ($33m) in a Series A financing round for advancing its Advanced Vectors-Ligand Conjugates (ALIGATER) platform.

The science has proven that gene therapies are effective treatments, and they have given hope to patients and their families ...

Discover why Danaher is a strong investment choice with its wide moat business model, M&A strategy, and growth potential for ...

The board of directors for Covington Life Sciences Partners Inc. has announced Christin Godale as its next executive director ...

In this guest commentary, Caleb Appleton, a principal at Bison Ventures, offers up a framework biotech founders can use to ...

Over 300 Participants Have Completed Cumulative Six Months of Cytisinicline Treatment in the ORCA-OL Trial, Completing the Long-Term Exposure ...

Dec. 30, 2024 — A new species of black, slender moray eel has chosen the road less traveled, thriving in dim and muddy river mouths, unlike most of its marine ... Six New Tree Species Named: 3 ...

An Austin biotech company is laying off a third of its staff following news that its primary drug candidate didn't produce ...

A single amino acid change in a neuronal ion channel called KCNQ2 blocks ion flow, prevents protein localization on axons, and results in severe epilepsy and slowed neurological development.

Challenge trials help researchers study immune responses. Skeptics still doubt the approach is worth the risks ...